Merus receives EP patent covering the expression of defined antibody combinations

21-Jun-2012 - Netherlands

Merus B.V. announced today that it has been granted the first European patent covering its Oligoclonics® technology from a patent family that already comprises 4 issued US patents. The Oligoclonics® technology entails the manufacturing of at least three antibodies with different specificities by a single production cell line, thereby providing for combinations of human antibodies as a single therapeutic.

“The therapeutic antibody field is moving towards combination therapies, either by combining individual monoclonal antibodies or by applying bispecific formats, to overcome the limited potency of monoclonal antibodies often observed in indications like oncology,” said Ton Logtenberg, CEO of Merus. “The Oligoclonics® technology provides a platform that allows for the cost-effective development and manufacturing of multispecific combinations of antibodies with more potent clinical effects. The key to the Oligoclonics® technology is that all antibodies produced by the clonal manufacturing cell line share a common light chain (cLC). With our recent announcement of MeMo®, a transgenic mouse for the generation of human cLC monoclonal antibodies, we are complementing our technology base with the aim to expand our pipeline of innovative cLC antibody products.”  

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous